CN106706623A - Kit for rapidly detecting ischemia modified albumin and application of kit - Google Patents
Kit for rapidly detecting ischemia modified albumin and application of kit Download PDFInfo
- Publication number
- CN106706623A CN106706623A CN201611262953.0A CN201611262953A CN106706623A CN 106706623 A CN106706623 A CN 106706623A CN 201611262953 A CN201611262953 A CN 201611262953A CN 106706623 A CN106706623 A CN 106706623A
- Authority
- CN
- China
- Prior art keywords
- kit
- reagent
- modified albumin
- ischemia modified
- quick detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention belongs to the technical field of medical examination, and in particular relates to a kit for rapidly detecting ischemia modified albumin and application of the kit. The kit comprises a reagent R1 and a reagent R2, wherein the reagent R1 mainly consists of a glycine-sodium hydroxide buffer solution, cobalt chloride, hexadecyl trimethyl ammonium chloride and a preservative; and the reagent R2 mainly consists of a trihydroxymethyl aminomethane buffer solution, alpha-pyridine azo-beta-naphthol, hexadecyl trimethyl ammonium chloride, dipotassium phosphate, a stabilizing agent and a preservative. The kit for rapidly detecting ischemia modified albumin, which is provided by the invention, is high in detection result precision, good in repeatability and good in interference resistance, also has the advantages of being good in stability, low in price and easy to preserve, is a relatively ideal ischemia modified albumin detection kit, and is beneficial to clinical application of kits for rapidly detecting ischemia modified albumin.
Description
Technical field
The invention belongs to technical field of medical examination, and in particular to a kind of kit of quick detection ischemia modified albumin IMA
And its application.
Background technology
Human serum albumins (Human serum albumin, HSA) is the protein in human plasma, and its is nonglycosylated
Single chain polypeptide includes 585 amino acid, and molecular weight is 66kD.Human serum albumins in the presence of oxygen radical, its amino acid
End structure changes, the albumin for causing it to weaken with some exotic metallic cobalts, copper, nickel binding ability, referred to as ischemic
Modified albumin (ischemia modified albumin, IMA).In recent years, many research discoveries, ischemia modified albumin IMA
It is a kind of preferable biochemical marker of acute myocardial ischemia.It is deficiency decorated compared with traditional acute myocardial ischemia mark
Albumin (IMA) blood middle concentration within the short time of ischemic episode will be raised, and now the irreversibility of cardiac muscle cell is damaged
Wound has not occurred, therefore, IMA has more early diagnosis value, is capable of the diagnosis of adjuvant clinical doctor clear and definite myocardial ischemia as early as possible, from
And carry out early intervention and treatment.
The assay method of IMA is that, using Cobalt binding test method, its Cleaning Principle is according to the relatively normal white eggs of IMA
It is white to combine the reduction of metallic cobalt ion energy, a certain amount of cobalt ions is added in reaction system, and by determining free cobalt ions
Concentration, extrapolate the content of IMA.Because the testing result has testing result poor repeatability, testing result is unstable to be lacked
Point.In order to improve the repeatability and accuracy of testing result, developer is added to react product with free cobalt during detection
Raw color, with its absorbance size of spectrophotometric determination, such that it is able to accurately measure the content of IMA in serum.
The specificity and sensitivity that developer is combined with cobalt ions are the key factors for improving detection IMA accuracys.At present
Conventional developer has：Dithioerythritol, dithiothreitol (DTT), thiadiazoles azo dimethyl p-aminophenol, 2- (5- nitro -2- pyrroles
Pyridine azo) -3,6- naphtholdisulfonic acids, 5- (5- nitro -2- pyridylazos) -2,4 di amino toluene, 2- (1,3,4- triazole idols
Nitrogen) -5- diethylamino phenols, 2- (5- ethyl thiadiazoles azo) -5- Dimethylaminophenols and 1-Nitroso-2-naphthol etc. colour developing
Agent.
Patent document CN103674938A disclosed a kind of ischemia modified albumin IMA combine measured examination on the 10th in September in 2012
Agent, assay method and kit, the albumin combination mensuration reagent of ischemia modification is using dithiothreitol (DTT) as free cobalt ions
Developer, can improve the definition of testing result.But, dithiothreitol (DTT) easily receives exotic metallic ion interference, and
The easy oxidation by air of dithiothreitol (DTT), stability is poor, it is difficult to preserve, and is unfavorable for the promotion and application of the detection reagent.
Patent document CN103558397A on November 4th, 2013 disclose a kind of ischemia modified albumin IMA detection reagent and
Detection method, developer of the detection reagent using thiadiazoles azo dimethyl p-aminophenol as free cobalt ions, thiadiazoles azo
Dimethyl p-aminophenol is it is possible to prevente effectively from the interference of the metal ion such as Pd, Ni, Zn and Cu.But, the dynamics of the detection reagent
Curve is not good, and the range of linearity is narrow, have impact on the reappearance and stability of experiment.
Therefore, study and hair is outputed a kind of reproducible, detection precision quick detection ischemic high and good stability and repaiied
The kit for adoring albumin is the problem of current urgent need to resolve.
The content of the invention
In order to there is measurement result poor repeatability, detection precision in the kit for overcoming prior art ischemia modified albumin IMA
The shortcoming of low and stability difference.It is an object of the invention to provide a kind of quick detection ischemia modified albumin IMA kit and its
Using above-mentioned to solve the problems, such as.
The invention provides a kind of kit of quick detection ischemia modified albumin IMA, the kit include reagent R1 and
Reagent R2, the reagent R1 include following components：
Glycine-NaOH buffer solution 90-140mmol/L, cobalt chloride 50-80mmol/L, cetyl trimethyl chlorine
Change ammonium 2-6mol/L and preservative 0.05-0.2mol/L；
The reagent R2 includes following components：TRIS buffer 90-140mmol/L, α-pyridylazo-
Betanaphthol 20-40mmol/L, hexadecyltrimethylammonium chloride 2-6mol/L, dipotassium hydrogen phosphate 0.1-0.3mol/L, stabilizer
1-5mmol/L and preservative 0.05-0.2mol/L.
Further, the kit includes that reagent R1 and reagent R2, the reagent R1 include following components：
Glycine-NaOH buffer solution 120mmol/L, cobalt chloride 70mmol/L, hexadecyltrimethylammonium chloride
4mol/L and preservative 0.08mol/L；
The reagent R2 includes following components：TRIS buffer 120mmol/L, α-pyridylazo-β-
Naphthols 32mmol/L, hexadecyltrimethylammonium chloride 4mol/L, dipotassium hydrogen phosphate 0.2mol/L, stabilizer 3mmol/L and anti-
Rotten agent 0.08mol/L.
Further, the pH value of the Glycine-NaOH buffer solution is 8.5-9.0.
Further, the pH value of the TRIS buffer is 7.5-8.5.
Further, the stabilizer by sodium alginate and sodium oxalate by weight (4-6):(1-3) is constituted.
Further, the stabilizer is by sodium alginate and sodium oxalate by weight 5:2 compositions.
Further, the preservative is proclin300.
Further, the volume ratio of the reagent R1 and reagent R2 is 6:1.
In addition, detecting deficiency decorated white present invention also offers a kind of kit of quick detection ischemia modified albumin IMA
Application in albumen.
Hexadecyltrimethylammonium chloride in the kit of the quick detection ischemia modified albumin IMA that the present invention is provided
Molecular formula is C19H42ClN, No. CAS is 112-02-7；The molecular formula of α-pyridylazo-betanaphthol is C15H11N3O, No. CAS is
85-85-8；No. CAS of sodium alginate is 9005-38-3.
The Cleaning Principle of kit of the quick detection ischemia modified albumin IMA that the present invention is provided is：According to deficiency decorated white
The property that protein binding metallic cobalt ion energy weakens is quantitative determined.Albumin is with activity in the blood serum sample of normal control
Form is present, and after adding cobalt chloride solution, cobalt ions can be combined with albumin N-terminal, and dissociate cobalt ions present in solution
Concentration is relatively low；And contain more ischemia modified albumin IMA in the individual blood serum sample of ischemic, add the cobalt chloride of same concentration
, due to ischemia modified albumin IMA and the reduction of cobalt ions binding ability, there is the free cobalt ions of higher concentration in solution, profit in solution
Combined with free cobalt ions with α-pyridylazo-betanaphthol in reagent and produced red complex compound, ischemia modified albumin IMA content
Color intensity with complex compound is proportional, and absorbance is detected under 505nm, can carry out quantitative survey to ischemia modified albumin IMA indirectly
It is fixed.
The kit of the quick detection ischemia modified albumin IMA that the present invention is provided is using α-pyridylazo-betanaphthol as free
The developer of cobalt ions.Found through experiment, the hexadecyltrimethylammonium chloride that the present invention is provided can effective α-pyridine idol
Nitrogen-betanaphthol can detect the cobalt ions of low concentration to the detection sensitivity of cobalt ions, such that it is able to significantly increase inspection
The accuracy and precision of test agent.
Further, what the present invention was provided can be had with sodium oxalate by sodium alginate by the stabilizer that certain weight ratio is constituted
The stability and repeatability of the raising kit testing result of effect.Found through experiment, sodium alginate can be in cobalt ions and colour developing
Dosage form into complex compound surface form diaphragm, prevent cobalt ions and developer from departing from, cause testing result unstable, Ke Yijin
One step ground improves the Stability and veracity of kit testing result, is a kind of detection of ideal ischemia modified albumin IMA
Reagent.
In a word, compared with prior art, the kit detection knot of the quick detection ischemia modified albumin IMA that the present invention is provided
Fruit precision is high, reproducible, strong antijamming capability, and its also have good stability, it is cheap, it is easy to preservation it is excellent
Point, is a kind of detection kit of ideal ischemia modified albumin IMA, is conducive to the quick detection ischemia modified albumin IMA
Kit clinical practice.
Specific embodiment
The present invention is further described below by way of specific embodiment, the present invention is not limited only to following examples.In this hair
In bright scope or not departing from present disclosure, spirit and scope, the change that is carried out to the present invention, combine or replace
Change, will be apparent to the person skilled in the art, and be included within the scope of the present invention.
Embodiment 1, a kind of kit of quick detection ischemia modified albumin IMA
The kit of the quick detection ischemia modified albumin IMA includes that volume ratio is 6:1 reagent R1 and reagent R2,
The reagent R1 is composed of the following components：PH value is 8.5 Glycine-NaOH buffer solution 90mmol/L, chlorine
Change cobalt 50mmol/L, hexadecyltrimethylammonium chloride 2mol/L and proclin3000.05mol/L.
The preparation method of reagent R1 is：Cobalt chloride, hexadecyltrimethylammonium chloride and proclin300 are added into pH value
To be stirred in 8.5 Glycine-NaOH buffer solution, obtain final product.
The reagent R2 is composed of the following components：PH value be 7.5 TRIS buffer 90mmol/L, α-
Pyridylazo-betanaphthol 20mmol/L, hexadecyltrimethylammonium chloride 2mol/L, dipotassium hydrogen phosphate 0.1mol/L, stabilizer
2mmol/L and proclin3000.05mol/L；The stabilizer is by sodium alginate and sodium oxalate by weight 4:3 compositions.
The preparation method of reagent R2 is：By α-pyridylazo-betanaphthol, hexadecyltrimethylammonium chloride, phosphoric acid hydrogen two
Potassium, stabilizer and proclin300 stir in adding the TRIS buffer that pH value is 7.5, obtain final product, institute
Stabilizer is stated by sodium alginate and sodium oxalate by weight 4:3 compositions.
Embodiment 2, a kind of kit of quick detection ischemia modified albumin IMA
The kit of the quick detection ischemia modified albumin IMA includes that volume ratio is 6:1 reagent R1 and reagent R2,
The reagent R1 is composed of the following components：PH value is 8.8 Glycine-NaOH buffer solution 120mmol/L, chlorine
Change cobalt 70mmol/L, hexadecyltrimethylammonium chloride 4mol/L and proclin3000.08mol/L.
The preparation method of reagent R1 is similar to Example 1.
The reagent R2 is composed of the following components：PH value be 8.2 TRIS buffer 120mmol/L,
α-pyridylazo-betanaphthol 32mmol/L, hexadecyltrimethylammonium chloride 4mol/L, dipotassium hydrogen phosphate 0.2mol/L, stabilization
Agent 3mmol/L and proclin3000.08mol/L；The stabilizer is by sodium alginate and sodium oxalate by weight 5:2 compositions.
The preparation method of reagent R2 is similar to Example 1.
Embodiment 3, a kind of kit of quick detection ischemia modified albumin IMA
The kit of the quick detection ischemia modified albumin IMA includes that volume ratio is 6:1 reagent R1 and reagent R2,
The reagent R1 is composed of the following components：PH value is 9.0 Glycine-NaOH buffer solution 140mmol/L, chlorine
Change cobalt 80mmol/L, hexadecyltrimethylammonium chloride 6mol/L and proclin3000.1mol/L.
The preparation method of reagent R1 is similar to Example 1.
The reagent R2 is composed of the following components：PH value be 8.5 TRIS buffer 140mmol/L,
α-pyridylazo-betanaphthol 40mmol/L, hexadecyltrimethylammonium chloride 6mol/L, dipotassium hydrogen phosphate 0.3mol/L, stabilization
Agent 5mmol/L and proclin3000.1mol/L；The stabilizer is by sodium alginate and sodium oxalate by weight 6:1 composition.
The preparation method of reagent R2 is similar to Example 1.
Comparative example 1, a kind of kit of quick detection ischemia modified albumin IMA
The kit of the quick detection ischemia modified albumin IMA includes that volume ratio is 6:1 reagent R1 and reagent R2,
The reagent R1 is composed of the following components：PH value is 8.8 Glycine-NaOH buffer solution 120mmol/L, chlorine
Change cobalt 70mmol/L, Tween 80 4mol/L and proclin3000.08mol/L.
The preparation method of reagent R1 is similar to Example 1.
The reagent R2 is composed of the following components：PH value be 8.2 TRIS buffer 120mmol/L,
α-pyridylazo-betanaphthol 32mmol/L, Tween 80 4mol/L, dipotassium hydrogen phosphate 0.2mol/L, stabilizer 3mmol/L and
proclin3000.08mol/L；The stabilizer is by sodium alginate and sodium oxalate by weight 5:2 compositions.
The preparation method of reagent R2 is similar to Example 1.
Difference with embodiment 2 is that hexadecyltrimethylammonium chloride is replaced with into Tween 80.
Comparative example 2, a kind of kit of quick detection ischemia modified albumin IMA
The kit of the quick detection ischemia modified albumin IMA includes that volume ratio is 6:1 reagent R1 and reagent R2,
The reagent R1 is composed of the following components：PH value is 8.8 Glycine-NaOH buffer solution 120mmol/L, chlorine
Change cobalt 70mmol/L, hexadecyltrimethylammonium chloride 4mol/L and proclin3000.08mol/L.
The preparation method of reagent R1 is similar to Example 1.
The reagent R2 is composed of the following components：PH value be 8.2 TRIS buffer 120mmol/L,
α-pyridylazo-betanaphthol 32mmol/L, hexadecyltrimethylammonium chloride 4mol/L, dipotassium hydrogen phosphate 0.2mol/L, oxalic acid
Sodium 3mmol/L and proclin3000.08mol/L.
The preparation method of reagent R2 is similar to Example 1.
Difference with embodiment 2 is that the stabilizer is sodium oxalate.
Comparative example 3, a kind of kit of quick detection ischemia modified albumin IMA
The kit of the quick detection ischemia modified albumin IMA includes that volume ratio is 6:1 reagent R1 and reagent R2,
The reagent R1 is composed of the following components：PH value is 8.8 Glycine-NaOH buffer solution 120mmol/L, chlorine
Change cobalt 70mmol/L, hexadecyltrimethylammonium chloride 4mol/L and proclin3000.08mol/L.
The preparation method of reagent R1 is similar to Example 1.
The reagent R2 is composed of the following components：PH value be 8.2 TRIS buffer 120mmol/L,
α-pyridylazo-betanaphthol 32mmol/L, hexadecyltrimethylammonium chloride 4mol/L, dipotassium hydrogen phosphate 0.2mol/L, stabilization
Agent 3mmol/L and proclin3000.08mol/L；The stabilizer is by sodium alginate and sodium oxalate by weight 1:1 composition.
The preparation method of reagent R2 is similar to Example 1.
Difference with embodiment 2 is that the stabilizer is by sodium alginate and sodium oxalate by weight 1:1 composition.
Test example one, a kind of precision test of the kit of quick detection ischemia modified albumin IMA
1st, test material：The quick detection that embodiment 1, embodiment 2, embodiment 3 and comparative example 1 are prepared is deficiency decorated
The kit of albumin；The ischemia modified albumin IMA standard items of high and low concentration value, are purchased from sigma companies.
2nd, test method：
2.1st, withinrun precision detection：High and low concentration value is respectively the ischemia modified albumin IMA of 81.0 and 62.0U/mL
Standard items are distributed into 20 parts respectively, and the quick detection prepared using embodiment 1, embodiment 2, embodiment 3 and comparative example 1 is lacked
The kit of blood modified albumin continuously detects the ischemia modified albumin IMA standard items 20 times of high and low concentration value, calculate batch in become
Different coefficient.
2.2nd, betweenrun precision detection：High and low concentration value is respectively the ischemia modified albumin IMA of 81.0 and 62.0U/mL
Standard items are distributed into 10 parts respectively, are put in -20 DEG C of Refrigerator stores, are made using embodiment 1, embodiment 2, embodiment 3 and comparative example 1
The kit of the standby quick detection ischemia modified albumin IMA for obtaining detects the ischemia modified albumin IMA standard of high and low concentration value daily
Product 1 time, continuous detection 10 days, calculate interassay coefficient of variation.
3rd, result of the test：
Result of the test is as shown in Table 1 and Table 2.
The variation within batch coefficient (n=20) of the kit of the quick detection ischemia modified albumin IMA of table 1
The interassay coefficient of variation (n=10) of the kit of the quick detection ischemia modified albumin IMA of table 2
From Tables 1 and 2, the kit detection of the quick detection ischemia modified albumin IMA that the present invention is provided batch in and
The coefficient of variation between batch is less than 5%, illustrates the kit of quick detection ischemia modified albumin IMA of present invention offer with higher
Precision and repeatability.
Test example two, a kind of stability test of the kit of quick detection ischemia modified albumin IMA
1st, test material：Quick detection ischemic prepared by embodiment 1, embodiment 2, embodiment 3, comparative example 2 and comparative example 3
The kit of modified albumin；Pooled serum sample, is purchased from the refined Anda Bioisystech Co., Ltd in Beijing.
2nd, test method：Use automatic clinical chemistry analyzer to be measured with Two point end assay, using embodiment 1, implement
The kit METHOD FOR CONTINUOUS DETERMINATION mixing of quick detection ischemia modified albumin IMA prepared by example 2, embodiment 3, comparative example 2 and comparative example 3
Blood serum sample 50 times, calculates the average of absorbance, standard deviation, then pooled serum sample is sub-packed in into -18 DEG C of refrigerations, by reagent
Box is positioned over 4 DEG C of refrigerators, and then the same pooled serum sample of daily METHOD FOR CONTINUOUS DETERMINATION, calculates its difference, withFor standard is sentenced
It is disconnected whether to fail, Continuous Observation 10 days.
3rd, result of the test
The absorbance average of the pooled serum sample that First Determination is 50 times is 0.658, and standard deviation is 0.028,10 days in
Absorbance is shown in table 3.
The absorbance of the pooled serum sample of table 3
As shown in Table 3, the kit detection mixing of quick detection ischemia modified albumin IMA prepared by embodiment of the present invention 1-3
The absorbance of blood serum sample was 0.658 without departing from absorbance average at 10 days, and standard deviation is 0.028 scope, and contrasts
The absorbance of the kit detection pooled serum sample of quick detection ischemia modified albumin IMA prepared by example 2-3 exceeded at 10 days
Absorbance average is 0.658, and standard deviation is 0.028 scope, illustrate ischemia modified albumin IMA detection of the invention with very
Good stability.
Test example three, a kind of experiment of the anti-interference of kit of quick detection ischemia modified albumin IMA
1st, test material：The kit of quick detection ischemia modified albumin IMA prepared by embodiment 2；Pooled serum sample,
It is purchased from the refined Anda Bioisystech Co., Ltd in Beijing.
2nd, test method：Pooled serum sample is divided into 6 equal portions, 10 equal portions then will be divided into per equal portions, added different
Interfering material, makes its concentration in serum reach the requirement of table 4, and the content of IMA in serum is then determined respectively, and control group is surveyed
The measurement result of each group is shown in Table 4 wherein after determining result and adding disturbance material：Relative deviation (%)=(survey of interference sample
Determine the measure average of average-check sample) measure average × 100% of/check sample.
3rd, result of the test：
Result of the test is as shown in table 4.
The anti-interference test data of the kit of the quick detection ischemia modified albumin IMA of table 4
As shown in Table 4, the kit of quick detection ischemia modified albumin IMA prepared by the embodiment of the present invention 2 is in total bilirubin
Less than 560 μm of ol/L, Vitamin C content is less than 0.45g/L, and lactic acid content is less than 4.5mmol/L, and content of hemoglobin is less than
4.5g/L, content of triglyceride is not significantly interfered with when being less than 8mmol/L to test result.The quick inspection of present invention offer is provided
The kit for surveying ischemia modified albumin IMA has stronger antijamming capability.
Claims (9)
1. a kind of kit of quick detection ischemia modified albumin IMA, it is characterised in that the kit includes reagent R1 and examination
Agent R2, the reagent R1 include following components：
Glycine-NaOH buffer solution 90-140mmol/L, cobalt chloride 50-80mmol/L, hexadecyltrimethylammonium chloride
2-6mol/L and preservative 0.05-0.2mol/L；
The reagent R2 includes following components：
TRIS buffer 90-140mmol/L, α-pyridylazo-betanaphthol 20-40mmol/L, cetyl
Trimethyl ammonium chloride 2-6mol/L, dipotassium hydrogen phosphate 0.1-0.3mol/L, stabilizer 1-5mmol/L and preservative 0.05-
0.2mol/L。
2. the kit of quick detection ischemia modified albumin IMA as claimed in claim 1, it is characterised in that the kit bag
Including reagent R1 and reagent R2, the reagent R1 includes following components：
Glycine-NaOH buffer solution 120mmol/L, cobalt chloride 70mmol/L, hexadecyltrimethylammonium chloride 4mol/L
With preservative 0.08mol/L；
The reagent R2 includes following components：
TRIS buffer 120mmol/L, α-pyridylazo-betanaphthol 32mmol/L, cetyl trimethyl
Ammonium chloride 4mol/L, dipotassium hydrogen phosphate 0.2mol/L, stabilizer 3mmol/L and preservative 0.08mol/L.
3. the kit of quick detection ischemia modified albumin IMA as claimed in claim 1 or 2, it is characterised in that the sweet ammonia
The pH value of acid-sodium hydrate buffer solution is 8.5-9.0.
4. the kit of quick detection ischemia modified albumin IMA as claimed in claim 1 or 2, it is characterised in that three hydroxyl
The pH value of aminomethane buffer solution is 7.5-8.5.
5. the kit of quick detection ischemia modified albumin IMA as claimed in claim 1 or 2, it is characterised in that the stabilization
Agent is by sodium alginate and sodium oxalate by weight (4-6):(1-3) is constituted.
6. the kit of quick detection ischemia modified albumin IMA as claimed in claim 5, it is characterised in that the stabilizer by
Sodium alginate and sodium oxalate are by weight 5:2 compositions.
7. the kit of quick detection ischemia modified albumin IMA as claimed in claim 1 or 2, it is characterised in that the anti-corrosion
Agent is proclin300.
8. the kit of quick detection ischemia modified albumin IMA as claimed in claim 1 or 2, it is characterised in that the reagent
The volume ratio of R1 and reagent R2 is 6:1.
9. the kit of the quick detection ischemia modified albumin IMA as described in claim 1-8 is any is detecting deficiency decorated white egg
Application in white.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611262953.0A CN106706623A (en) | 2016-12-30 | 2016-12-30 | Kit for rapidly detecting ischemia modified albumin and application of kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611262953.0A CN106706623A (en) | 2016-12-30 | 2016-12-30 | Kit for rapidly detecting ischemia modified albumin and application of kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106706623A true CN106706623A (en) | 2017-05-24 |
Family
ID=58906357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611262953.0A Pending CN106706623A (en) | 2016-12-30 | 2016-12-30 | Kit for rapidly detecting ischemia modified albumin and application of kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106706623A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111751552A (en) * | 2020-06-18 | 2020-10-09 | 广州市伊川生物科技有限公司 | Ischemia modified albumin determination kit and use method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012012469A2 (en) * | 2010-07-19 | 2012-01-26 | Otago Innovation Limited | Signal biomarkers |
| CN104198729A (en) * | 2014-08-27 | 2014-12-10 | 宁波瑞源生物科技有限公司 | Steady ischemia modified albumin kit |
| CN105021609A (en) * | 2015-07-06 | 2015-11-04 | 广州金域医学检验中心有限公司 | Ischemia-modified albumin detection reagent and detection method thereof |
-
2016
- 2016-12-30 CN CN201611262953.0A patent/CN106706623A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012012469A2 (en) * | 2010-07-19 | 2012-01-26 | Otago Innovation Limited | Signal biomarkers |
| CN104198729A (en) * | 2014-08-27 | 2014-12-10 | 宁波瑞源生物科技有限公司 | Steady ischemia modified albumin kit |
| CN105021609A (en) * | 2015-07-06 | 2015-11-04 | 广州金域医学检验中心有限公司 | Ischemia-modified albumin detection reagent and detection method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111751552A (en) * | 2020-06-18 | 2020-10-09 | 广州市伊川生物科技有限公司 | Ischemia modified albumin determination kit and use method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103760357B (en) | A kind of ischemia modified albumin IMA detection kit | |
| CN103695380B (en) | Fructosyl amino acid oxidase, preparation method and the glycosylated albumin detection kit containing this enzyme | |
| CN101458257B (en) | Kit for detecting ischemia modified albumin and method for making same | |
| CN102507916B (en) | Ischemia modified albumin liquid stabilization kit | |
| Rubinstein et al. | The colorimetric estimation of alpha-amino nitrogen in tissue fluids | |
| CN106124779A (en) | A kind of test kit for measuring creatinine and method | |
| CN106198509A (en) | For measuring test kit and the method for creatinine | |
| CN108414767A (en) | Glycosylated hemoglobin assay kit | |
| Wang et al. | Rapid kinetic rate assay of the serum α-L-fucosidase in patients with hepatocellular carcinoma by using a novel substrate | |
| EP0137400A2 (en) | Determination of unsaturated iron-binding capacity | |
| CN114807296A (en) | Human serum succinic acid detection kit | |
| CN106443014B (en) | Detection kit of ischemia modified albumin IMA and preparation method thereof | |
| CN106706623A (en) | Kit for rapidly detecting ischemia modified albumin and application of kit | |
| CN108690868B (en) | Adenosine deaminase determination kit and determination method thereof | |
| Lugg | Sullivan's reaction for the quantitative determination of cysteine and cystine | |
| CN105021609A (en) | Ischemia-modified albumin detection reagent and detection method thereof | |
| CN108103142A (en) | A kind of free-fat acid detection kit and preparation method thereof | |
| CN106370648A (en) | Detection kit with stable unsaturated iron-binding capacity | |
| US4072627A (en) | Uric acid determination | |
| Skala et al. | Methodology for determination of blood aminotransferases | |
| Yamakita et al. | Effect of urine storage on urinary uric acid concentrations | |
| Spiegel et al. | Semiautomated method for measurement of dopa in plasma | |
| CN113720836A (en) | Kit for detecting serum copper ions and preparation method thereof | |
| CN106053851A (en) | Prealbumin detection kit with high stability | |
| CN104195221B (en) | A kind of compound stabilizer for Glucose estimation kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |
|
| RJ01 | Rejection of invention patent application after publication |